Auger W R
Division of Pulmonary and Critical Care (8381), University of California, San Diego, Medical Center 92103, USA.
Curr Opin Pulm Med. 1995 Jul;1(4):303-12.
An ever-expanding body of information has provided new insights into the pathophysiologic mechanisms contributing to pulmonary hypertensive disease. The pulmonary endothelial cell has been shown to have a central role in both the maintenance of normal vascular tone and in the pathogenesis of small vessel changes. The relationship between endothelium-derived mediators such as nitric oxide, prostacyclin, and endothelin-1 is likely to be important in the development of abnormal vasomotor tone and structure in the pulmonary vascular bed. Stimulated by this evolving understanding of pulmonary vascular physiology, recent literature abounds with references to novel therapeutic strategies in the care of patients who have both primary and secondary forms of pulmonary hypertension. Advances in surgical technologies have also expanded the therapeutic options for selected groups of pulmonary hypertensive patients. This article highlights recent developments in the understanding of pulmonary vascular pathophysiology and examines strategies for evaluation and treatment of pulmonary hypertension and cor pulmonale.
越来越多的信息为导致肺动脉高压疾病的病理生理机制提供了新的见解。肺内皮细胞已被证明在维持正常血管张力和小血管病变的发病机制中都起着核心作用。内皮衍生介质如一氧化氮、前列环素和内皮素-1之间的关系可能在肺血管床异常血管舒缩张力和结构的发展中起重要作用。受对肺血管生理学不断发展的理解的刺激，最近的文献大量提及了原发性和继发性肺动脉高压患者护理中的新型治疗策略。外科技术的进步也扩大了特定组肺动脉高压患者的治疗选择。本文重点介绍了对肺血管病理生理学理解的最新进展，并探讨了肺动脉高压和肺心病的评估和治疗策略。
